We’re pleased to share that we’ve achieved a significant milestone: The last patient in the SANS-UUI pivotal clinical trial has completed their primary endpoint visit! The SANS-UUI multi-center clinical study was designed to demonstrate the safety and efficacy of the Neuspera System and gain FDA approval in the U.S. “We’re grateful to every physician and patient who participated in the clinical trial, and we’re excited that our uniquely differentiated technology will be available to millions of patients when it is FDA-approved for treatment of OAB symptoms,” said Steffen Hovard, CEO of Neuspera Medical. “The fact that the market is only 5% penetrated at this time is a clear indication that patients are looking for something different than what's available today. The Neuspera System delivers true innovation.” Check out the news here: https://lnkd.in/gygMz_AF. #OAB #urology #incontinence #neuromodulation
Amazing milestone! Incredible group effort!
Huge congrats!
Co-Founder & Technical Director @ PULSAR Microelectronics
3moWay to go Alex. Well deserved. Congratulations to the whole team.